Oral Administration or Nasal Feeding of Huzhangxiefei Decoction for Treatment in Sepsis Induced Acute Lung Injury
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Hypothesis 1A: Oral Administration or Nasal Feeding of Huzhangxiefei Decoction will
significantly attenuate sepsis-induced systemic organ failure as measured by Sequential Organ
Failure Assessment (SOFA) score, Hypothesis 1B: Oral Administration or Nasal Feeding of
Huzhangxiefei Decoction will attenuate sepsis-induced lung injury as assessed by the
oxygenation index and the VE40 Hypothesis 1C: Oral Administration or Nasal Feeding of
Huzhangxiefei Decoction will attenuate biomarkers of inflammation (C-Reactive Protein,
Procalcitonin), vascular injury (Thrombomodulin, Angiopoietin-2), alveolar epithelial injury
(Receptor for Advanced Glycation Products), while inducing the onset of a fibrinolytic state
(Tissue Factor Pathway Inhibitor).
Phase:
N/A
Details
Lead Sponsor:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine